As­traZeneca scores or­phan sta­tus for PD-L1/CT­LA-4 com­bo; EMA OKs No­var­tis' MS drug Mayzent

6 years ago
News Briefing

What do Mass Gen­er­al, the NCI and Mayo Clin­ic have in com­mon? They rou­tine­ly blow off an FDA rule on post­ing tri­al ...

6 years ago
R&D

Boehringer, No­vo-backed Ger­man biotech banks €11M in liv­er re­gen­er­a­tion push

6 years ago
Financing
Startups

Ko­re­a's Cell­tri­on blue­prints $514M bi­o­log­ics plant in Chi­na, beef­ing up biosim­i­lar, con­tract man­u­fac­tur­ing

6 years ago
Outsourcing

GSK’s ‘break­through’ BC­MA can­cer drug gets a pri­or­i­ty re­view — and a big win for the on­col­o­gy R&D team

6 years ago
R&D

Who are the young bio­phar­ma lead­ers shap­ing the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

6 years ago
Editor's note

BeiGene lines up its first shot at crack­ing the megablock­buster PD-1 mar­ket for lung can­cer. But can they over­come ...

6 years ago
R&D

FDA to al­low on­line sub­mis­sions of or­phan des­ig­na­tion re­quests

6 years ago
FDA+

Sci­en­tists find un­ex­pect­ed an­ti-can­cer ac­tiv­i­ty in range of non-on­col­o­gy drugs — study

6 years ago
R&D
Discovery

As­traZeneca nabs pri­or­i­ty re­view for Lyn­parza in prostate as PARP in­hibitors ex­pand to more can­cers

6 years ago
R&D

'Y­ou be­trayed that du­ty': For­mer con­gress­man Chris Collins sen­tenced to 26 months in jail for in­sid­er trad­ing

6 years ago
People

Bernie Sanders goes af­ter Bio­Mar­in's shot at a record drug price, threat­en­ing to break the patent

6 years ago
People
Bioregnum

Rev­o­lu­tion Med shoots for $100M+ IPO — and di­vulges some se­crets about that Warp Dri­ve buy­out

6 years ago
R&D

At #JPM20, two CEOs, two rad­i­cal­ly dif­fer­ent ther­a­pies, and a fight to chase down sick­le cell

6 years ago
R&D
Cell/Gene Tx

Pe­ter Ciriel­lo takes over the reins at Vy­gon USA; Mirum Phar­ma­ceu­ti­cals taps Ian Clements to the role of CFO

6 years ago
Peer Review

In­ter­cep­t's NASH de­ci­sion date is de­ferred; EMA in­ves­ti­gates safe­ty of LEO Phar­ma gel

6 years ago
News Briefing

Chi­na’s fourth rich­est man takes a back seat at the top drug­mak­er he built

6 years ago
People
China

No­vo Nordisk's block­buster Ozem­pic wins FDA la­bel boost with CV in­di­ca­tion

6 years ago
R&D

In ac­tive shop­ping mode, Eli Lil­ly plots one deal per quar­ter as it scouts 'Der­mi­ra-like' as­sets up to $5B

6 years ago
Deals

First Chi­nese biotech on Nas­daq in two years draws $104M

6 years ago
Financing

Ger­many’s IQWiG finds first tu­mor-ag­nos­tic drug pro­vides no added ben­e­fit

6 years ago
FDA+

Hung ju­ry vote leaves FDA with a dif­fi­cult de­ci­sion on Durec­t's non-opi­oid painkiller

6 years ago
R&D
FDA+

Bio­Marin ex­ecs dis­cuss some eye-pop­ping num­bers for the price of val­rox — but haven't we heard this be­fore?

6 years ago
R&D

#JPM20: Five years af­ter first PC­SK9, No­var­tis goes for win as Sanofi moves on, Am­gen sal­vages what's left

6 years ago
R&D
First page Previous page 861862863864865866867 Next page Last page
A service from the Financial Times